SEI Investments’s CRISPR Therapeutics CRSP Stock Holding History

SEI Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$668K	Sell	12,245 -3,580	-23%	-$189K	﹤0.01%	2520
2026 Q1	$753K	Buy	15,825 +3,167	+25%	+$167K	﹤0.01%	2495
2025 Q4	$664K	Buy	12,658 +516	+4%	+$30.9K	﹤0.01%	2380
2025 Q3	$787K	Buy	12,142 +728	+6%	+$41.8K	﹤0.01%	2065
2025 Q2	$555K	Buy	+11,414	New	+$442K	﹤0.01%	2140
2023 Q4	–	Sell	-55,455	Closed	-$2.52M	–	2623
2023 Q3	$2.52M	Sell	55,455 -2,414	-4%	-$125K	﹤0.01%	1487
2023 Q2	$3.25M	Sell	57,869 -6,764	-10%	-$384K	0.01%	1410
2023 Q1	$2.92M	Buy	+64,633	New	+$3.14M	0.01%	1453
2022 Q4	–	Sell	-54,179	Closed	-$3.54M	–	2560
2022 Q3	$3.54M	Buy	54,179 +2,494	+5%	+$181K	0.01%	1260
2022 Q2	$3.14M	Buy	+51,685	New	+$3.04M	0.01%	1336
2022 Q1	–	Sell	-3,240	Closed	-$247K	–	2597
2021 Q4	$247K	Sell	3,240 -576	-15%	-$50.3K	﹤0.01%	2401
2021 Q3	$427K	Buy	3,816 +642	+20%	+$80.6K	﹤0.01%	2146
2021 Q2	$514K	Buy	3,174 +817	+35%	+$99.4K	﹤0.01%	2080
2021 Q1	$287K	Buy	2,357 +256	+12%	+$38.7K	﹤0.01%	2267
2020 Q4	$322K	Buy	+2,101	New	+$248K	﹤0.01%	2178
2018 Q3	–	Sell	-800	Closed	-$47K	–	2648
2018 Q2	$47K	Hold	800	–	–	﹤0.01%	2532
2018 Q1	$37K	Buy	+800	New	+$33K	﹤0.01%	2452

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SEI Investments's CRSP Position: Q2 2026 in Review

SEI Investments reduced its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, selling an estimated $189K and leaving 12,245 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #2520.

SEI Investments first reported a position in CRSP in Q1 2018 and has held it in 17 quarters since. The position peaked at $3.54M in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

SEI Investments held 12,245 shares of CRISPR Therapeutics worth $668K as of Q2 2026.
SEI Investments sold 3,580 CRISPR Therapeutics shares in Q2 2026, an estimated $189K.
CRISPR Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2520 holding.
SEI Investments first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 17 quarters since.
SEI Investments's CRISPR Therapeutics position peaked at $3.54M in Q3 2022.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.